DeepMind AI Identifies Senhwa Drug Candidate for Cancer Immunotherapy

Google’s DeepMind has identified Senhwa Biosciences’ investigational drug Silmitasertib (CX-4945) as a potential pathway for cancer immunotherapy, announced in a press release. The finding came from DeepMind’s C2S-Scale model, developed in collaboration with Yale University, which analyzed tumor cell data and over 4,000 drug candidates.

The AI model predicted that inhibiting protein kinase CK2 with CX-4945 could significantly increase MHC-I expression and antigen presentation—key processes that help the immune system detect tumor cells. Laboratory results confirmed that treatment with CX-4945, combined with low-dose interferon, improved antigen presentation by around 50%.

Silmitasertib, a first-in-class CK2 inhibitor, is in clinical development for multiple cancer types and has shown a favorable safety record in patients. DeepMind’s validation of CX-4945 underscores its potential to enhance immune visibility of “cold” tumors, offering a new direction for immuno-oncology research.